Daily Endocrinology Research Analysis
Analyzed 112 papers and selected 3 impactful papers.
Summary
Three mechanistically rigorous studies redefine endocrine-metabolic biology: (1) liver stiffness mechanotransduces cholesterol accumulation via YAP/TAZ-mediated repression of LXRα in MASLD; (2) ER-associated degradation (SEL1L-HRD1) ensures prohormone convertase 2 maturation, sustaining glucagon biogenesis in islet α cells; and (3) CLCC1 emerges as a central ER factor coordinating hepatic neutral lipid flux and nuclear pore complex assembly. Together, they identify actionable nodes at the interfaces of mechanobiology, proteostasis, and lipid homeostasis.
Research Themes
- Mechanotransduction in metabolic liver disease and cholesterol homeostasis
- ER proteostasis controlling prohormone processing and glucagon biology
- Endoplasmic reticulum-driven coordination of hepatic lipid flux and nuclear pore assembly
Selected Articles
1. CLCC1 promotes hepatic neutral lipid flux and nuclear pore complex assembly.
This Nature study identifies CLCC1 as a key endoplasmic reticulum regulator that promotes hepatic neutral lipid flux while supporting nuclear pore complex assembly, thereby maintaining lipid homeostasis. The findings position CLCC1 at the nexus of ER membrane organization and lipid trafficking relevant to hepatic steatosis.
Impact: Revealing CLCC1 as a master coordinator of hepatic lipid flux and nuclear pore assembly reframes ER-centric control of liver lipid homeostasis and opens a new target space for steatotic liver disease.
Clinical Implications: Therapeutically modulating CLCC1 or its downstream pathways could restore lipid trafficking and prevent or reverse hepatic steatosis; mechanistic biomarkers linked to ER function and NPC assembly may refine risk stratification.
Key Findings
- CLCC1 is identified as an ER factor that promotes hepatic neutral lipid flux.
- CLCC1 supports nuclear pore complex assembly, linking ER membrane biology to nuclear transport architecture.
- These functions position CLCC1 as a central coordinator of hepatic lipid homeostasis with implications for steatosis.
Methodological Strengths
- High-impact mechanistic discovery directly connecting ER function to hepatic lipid flux and NPC assembly
- Clear pathophysiological relevance to hepatic steatosis articulated in the study focus
Limitations
- Preclinical mechanistic insights require validation in human clinical cohorts and intervention models
- Specific molecular intermediates and druggability parameters are not delineated in the abstracted content
Future Directions: Define CLCC1 interactome and signaling to enable pharmacologic modulation; test CLCC1-targeted strategies in MASLD models and human biomarker-guided studies.
Imbalances in lipid storage and secretion lead to hepatic steatosis, the accumulation of lipid droplets in hepatocytes
2. Liver Stiffness Directs Intrahepatic Cholesterol Accumulation Through YAP/TAZ in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Liver stiffness mechanotransduces cholesterol accumulation by activating YAP/TAZ, which repress LXRα and disrupt LXRα–RXRα heterodimerization, driving hepatocyte cholesterol loading. Human and mouse data converge, and hepatocyte-specific Yap/Taz ablation enhances cholesterol efflux and attenuates fibrosis progression.
Impact: This study links a measurable biophysical property (stiffness) to a defined nuclear mechanotransduction pathway (YAP/TAZ–LXRα), establishing a causal axis for cholesterol dysregulation in MASLD and nominating YAP/TAZ–LXRα as a therapeutic lever.
Clinical Implications: Noninvasive stiffness metrics may predict cholesterol-driven hepatocyte dysfunction; targeting mechanotransduction (e.g., YAP/TAZ modulators) or restoring LXRα activity could mitigate cholesterol accumulation and fibrosis in MASLD.
Key Findings
- In human MASLD and mouse models, intrahepatic cholesterol strongly correlates with liver stiffness.
- Stiff matrices drive spontaneous cholesterol accumulation in isolated hepatocytes.
- YAP/TAZ activation mechanosensitively represses LXRα and disrupts LXRα–RXRα heterodimerization.
- Hepatocyte-specific Yap/Taz ablation enhances cholesterol efflux and delays cholesterol-induced fibrosis.
- Patient liver transcriptomics show inverse correlation between LXRα target genes and stiffness/YAP-TAZ activity.
Methodological Strengths
- Multisystem validation spanning human cohort data, mouse models, and in vitro mechanobiology
- Mechanistic dissection linking substrate stiffness to nuclear YAP/TAZ signaling and LXRα function
Limitations
- Human data are correlative; interventional proof in patients is pending
- Translatability of stiffness-modulating or YAP/TAZ-targeting therapies requires safety and efficacy studies
Future Directions: Evaluate pharmacologic YAP/TAZ or LXRα modulators in MASLD; integrate elastography with lipidomic biomarkers to stratify risk and monitor response.
Elevated liver stiffness is closely associated with morbidity and mortality in metabolic dysfunction-associated steatotic liver disease (MASLD). However, the contribution of increased stiffness to impaired liver function is poorly understood. Here, we demonstrate that hepatic cholesterol levels are determined by the stiffness of the liver. In the human MASLD cohort and a mouse model, intrahepatic cholesterol levels strongly correlated with liver stiffness. We show that a stiff matrix promotes spontaneous accumulation of cholesterol in isolated hepatocytes. As the underlying mechanism, we found that Liver X receptor alpha (LXRα) is mechanosensitively repressed. Activation of Yes-associated protein (YAP) and Transcriptional coactivator with PDZ-binding motif (TAZ) by exposure to stiff substrate, serum stimulation, low-density culture, or deletion of Large tumor suppressor kinase 1 and 2 (LATS1/2) robustly repressed LXRα activity. In the nucleus, YAP disrupted heterodimerization of LXRα with Retinoid X receptor alpha (RXRα) independently of their transcriptional activity. Consistently, hepatocyte-specific ablation of Yap/Taz facilitated hepatic cholesterol efflux and delayed cholesterol-induced fibrosis progression in mice. Transcriptomic analysis of MASLD patient livers confirmed a strong inverse correlation between LXRα target gene expression and liver stiffness as well as YAP/TAZ activity. These findings reveal the mechanosensitive regulation of hepatic cholesterol levels in MASLD, suggesting liver stiffness as a causal factor for hepatocyte dysfunction.
3. SEL1L-HRD1 ER-associated degradation facilitates prohormone convertase 2 maturation and glucagon production in islet α cells.
SEL1L-HRD1 ERAD targets misfolded proPC2 to enable maturation of activation-competent PC2 in the ER, sustaining glucagon biogenesis in α cells. Loss of SEL1L in proglucagon-expressing cells reduces stimulated glucagon secretion and pancreatic glucagon content, establishing ERAD as an essential regulator of α-cell function.
Impact: By uncovering ERAD control of prohormone convertase maturation, this work redefines proteostasis as a proximal determinant of glucagon biology and highlights ER quality control as a therapeutic axis in dysglycemia.
Clinical Implications: Therapeutic tuning of ERAD or PC2 maturation may modulate glucagon output in diabetes and hypoglycemia; ER stress/ERAD biomarkers could stratify α-cell dysfunction.
Key Findings
- SEL1L-HRD1 ERAD regulates turnover of nascent proPC2, enabling maturation of activation-competent PC2.
- SEL1L deletion in proglucagon-expressing cells reduces stimulated glucagon secretion and pancreatic glucagon content in mice.
- Endogenous proPC2 is an ERAD substrate, linking ER quality control directly to glucagon biogenesis in α cells.
Methodological Strengths
- Genetic loss-of-function in targeted α-cell lineage with functional secretion readouts
- Substrate-level assignment of ERAD to proPC2 with mechanistic linkage to hormone biogenesis
Limitations
- Findings are preclinical with murine models; human translational studies are needed
- Potential off-target effects of modulating ERAD pathways require careful safety assessment
Future Directions: Map ERAD-PC2 regulatory nodes for pharmacologic targeting; evaluate ER proteostasis modulators on α-cell function in diabetes models and human islets.
Proteolytic cleavage of proglucagon by prohormone convertase 2 (PC2) is required for islet α cells to generate glucagon. However, the regulatory mechanisms underlying this process remain largely unclear. Here, we report that SEL1L-HRD1 endoplasmic reticulum (ER)-associated degradation (ERAD), a highly conserved protein quality control system responsible for clearing misfolded proteins from the ER, plays a key role in glucagon production by regulating turnover of the nascent proform of the PC2 enzyme (proPC2). Using a mouse model with SEL1L deletion in proglucagon-expressing cells, we observe a progressive decline in stimulated glucagon secretion and a reduction in pancreatic glucagon content. Mechanistically, we find that endogenous proPC2 is a substrate of SEL1L-HRD1 ERAD, and that degradation of misfolded proPC2 ensures the maturation of activation-competent proPC2 protein in the ER. Here, we identify ERAD as a regulator of PC2 biology and an essential mechanism for maintaining α cell function.